Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orexigen On Quicker-Than-Expected Pace To Obtain Data Needed To Re-File NDA For Contrave

This article was originally published in The Pink Sheet Daily

Executive Summary

During its second quarter earnings call, the biotech said it sees recent FDA approvals of two other obesity drugs as a positive for its own prospects, but it is re-engaging with the agency on why it must perform a cardiovascular-outcomes trial prior to approval.

You may also be interested in...



Orexigen Eyes Earlier Resubmission Of Contrave NDA

The company is optimistic it can work out an agreement with FDA to re-file the obesity drug application before it has interim data from a cardiovascular outcomes trial in hand.

Orexigen Eyes Earlier Resubmission Of Contrave NDA

The company is optimistic it can work out an agreement with FDA to re-file the obesity drug application before it has interim data from a cardiovascular outcomes trial in hand.

FDA Sets Cautious Tone For Prescribing Newly Approved Obesity Drugs

Agency offers perspective in New England Journal of Medicine that lays out the case for careful use of drugs in a space with medical need but a long history of products with toxic side effects.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel